As a part of a major study on the pathophysiologic indices for recurrence of human breast cancer, preoperative eosinophil and lymphocyte counts were determined on 419 and 581 primary breast cancer patients, respectively. Patients with lymphocyte counts less than or equal to 1500/mm3 and/or eosinophil counts of less than 55/mm3 had significantly higher risk of recurrent disease than those patients who had normal or high levels of eosinophils and/or lymphocytes. These findings may indicate that the immunologic activities of eosinophils and lymphocytes enhance the patients' ability to respond against disease. Cancer 52:126‐130, 1983.
SummaryDetermination of the levels of prostaglandin E2 (PGE2) and PGF2~ were carried out using homogenized primary human breast tumors. Measurable levels of both prostaglandins were found in all but one tumor examined. In most samples, the absolute PGF2~ level was higher than that of PGE2. Higher PGE2 levels are more often seen in postmenopausal women than in pre-or perimenopausal patients, though among postmenopausal women, PGE2 levels do not correlate with age. Thus, the ratio of P G F : P G E is higher in pre/perimenopausal women than in postmenopausal women. Differences in PGF2~ do not appear to be associated with age or menopausal status.Tumors that are estrogen receptor positive (ER +) tend to have higher PGE2 levels than ER negative tumors. PGF2~ is not associated with the presence of ER and neither prostaglandin is associated with the presence of progesterone receptor. Higher levels of both PGE2 and PGF2~ are associated with less differentiated tumors, while tumor maximum diameter is negatively associated with PGE2 levels.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.